Clinical Trial Update: Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients [Phase 2]

View source ↗

Summary

Phase II study evaluating BILR 355 BS in HIV-1 infected, NNRTI-treated patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BILR 355 BS

Snippet

Sponsor: Boehringer Ingelheim | Conditions: HIV Infections | Phase 2 | Status: TERMINATED